254 related articles for article (PubMed ID: 22941027)
1. Prevention and treatment of myeloma bone disease.
Terpos E; Kastritis E; Dimopoulos MA
Curr Hematol Malig Rep; 2012 Dec; 7(4):249-57. PubMed ID: 22941027
[TBL] [Abstract][Full Text] [Related]
2. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
3. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
5. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
6. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
[TBL] [Abstract][Full Text] [Related]
7. Management of bone disease in multiple myeloma.
Terpos E; Berenson J; Raje N; Roodman GD
Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options in the management of myeloma bone disease.
Berenson JR
Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
12. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
14. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma bone disease: experimental and clinical data.
Papamerkouriou YM; Kenanidis E; Gamie Z; Papavasiliou K; Kostakos T; Potoupnis M; Sarris I; Tsiridis E; Kyrkos J
Expert Opin Biol Ther; 2015 Feb; 15(2):213-30. PubMed ID: 25388648
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates in multiple myeloma.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
